No Data
No Data
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). This shift could revolutionize the cannabis industry. B
Express News | NYSE Order Imbalance 280471.0 Shares on Sell Side
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
Cantor Fitzgerald has initiated coverage on AbbVie Inc (NYSE:ABBV), a global pharma company.The analyst notes that the company has positioned itself to absorb Humira biosimilar erosion and achieve mod
The Analyst Verdict: AbbVie In The Eyes Of 5 Experts
5 analysts have expressed a variety of opinions on AbbVie (NYSE:ABBV) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent rati
AbbVie Says It Will Present New Data Supporting Leading Gastroenterology Portfolio At 2024 Digestive Disease Week; Company To Present 15 Abstracts, Including Three Oral Presentations, In Crohn's Disease And Ulcerative Colitis
The 2024 Digestive Disease Week (DDW) Annual Meeting will be held on May 18-21 in Washington, D.C., and virtually.Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYR
AbbVie Initiated at Overweight by Cantor Fitzgerald
AbbVie Initiated at Overweight by Cantor Fitzgerald
No Data
Xiaobie : how do you read TRIPLE?